Related Experiment Video

Updated: Jul 16, 2026

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies

Klaus Podar1, Kenneth C Anderson

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA. klaus_podar@dfci.harvard.edu

Cell Cycle (Georgetown, Tex.)
|March 14, 2007
PubMed

Insights

Vascular endothelial growth factor (VEGF) drives cancer progression and drug resistance. VEGF inhibitors, like pazopanib, show promise in improving outcomes for multiple myeloma (MM) patients.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Vascular Endothelial Growth Factor (VEGF) is crucial in tumor development, metastasis, and drug resistance.
  • VEGF signaling impacts various cell types, including endothelial, stem, immune, bone, and nerve cells.
  • Antiangiogenic therapies targeting VEGF have transformed cancer treatment.

Purpose of the Study:

  • To explore the role of VEGF in hematologic malignancies, specifically multiple myeloma (MM).
  • To investigate the potential of VEGF inhibitors as a therapeutic strategy for MM.

Main Methods:

  • Review of existing literature on VEGF's role in cancer and MM.
  • Analysis of the mechanisms of action for VEGF inhibitors, such as pazopanib.
  • Evaluation of preclinical and clinical data regarding VEGF inhibition in MM.

Main Results:

  • VEGF is implicated in multiple myeloma (MM) pathogenesis, progression, and resistance to therapies.
  • VEGF inhibitors have demonstrated efficacy in solid tumors and are being explored for hematologic malignancies.
  • Pazopanib, a small molecule VEGF receptor inhibitor, shows potential therapeutic benefit in MM.

Conclusions:

  • VEGF plays a significant role in multiple myeloma (MM) and associated complications like metastatic osteolysis.
  • Targeting VEGF with inhibitors like pazopanib represents a promising therapeutic avenue for improving MM patient outcomes.
  • Further research and clinical trials are warranted to establish the efficacy of VEGF inhibitors in MM treatment regimens.

More Related Videos

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...